Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
SHAREHOLDER ALERT: WeissLaw LLP Investigates Translate Bio, Inc.
04:24pm, Tuesday, 03'rd Aug 2021
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Translate Bio, Inc. ("Translate" or
Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio
11:05am, Tuesday, 03'rd Aug 2021
Biotech stocks surge after big news & bullish analyst ratings. The post Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio appeared first on Penny Stocks to Buy, Picks, News and I
Sanofi to buy mRNA developer for $3.2 billion
08:15am, Tuesday, 03'rd Aug 2021
Shares of Translate Bio Inc. soared 29.8% in premarket trading on Tuesday after Sanofi said it will spend $3.2 billion to buy the developer of messenger RNA (mRNA) technologies. The U.S.-listed shares
Why Sanofi (SNY) Is Buying Translate Bio (TBIO) For $3.2 Billion
06:31am, Tuesday, 03'rd Aug 2021
Sanofi SA (NASDAQ: SNY) has announced it is buying Translate Bio (NASDAQ: TBIO) in a deal valued at about $3.2 billion. These are the details.
Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights
06:04am, Tuesday, 03'rd Aug 2021
A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi SA (NASDAQ: SNY) has announced a $3.2 b
Sanofi Buys U.S. Partner Translate Bio For $3.2 Billion As Pharma Giant Bets Big On mRNA Tech
04:17am, Tuesday, 03'rd Aug 2021
Pfizer, BioNTech and Moderna used mRNA to build effective Covid-19 vaccines in record time, a feat Sanofi is keen to build upon in the future.
Sanofi to acquire U.S.-based Translate Bio in deal valued at $3.2 billion
01:41am, Tuesday, 03'rd Aug 2021
Sanofi to acquire U.S.-based Translate Bio in deal valued at $3.2 billion
Sanofi confirms $3.2 billion offer to buy U.S. biotech firm Translate Bio
01:28am, Tuesday, 03'rd Aug 2021
French drugmaker Sanofi said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
Exclusive-Sanofi offers to buy U.S. mRNA partner Translate Bio -sources
05:46pm, Monday, 02'nd Aug 2021
PARIS (Reuters) -Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology a
Sanofi SA (SNY) CEO Paul Hudson on Q2 2021 Results - Earnings Call Transcript
06:16pm, Thursday, 29'th Jul 2021
Sanofi SA (SNY) CEO Paul Hudson on Q2 2021 Results - Earnings Call Transcript
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
02:28pm, Thursday, 29'th Jul 2021
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
Online availability of Sanofi's half-year financial report for 2021
12:24pm, Thursday, 29'th Jul 2021
Online availability of Sanofi's half-year financial report for 2021
Viatris gets FDA approval of first biosimilar version of Sanofi's insulin Lantus
08:12am, Thursday, 29'th Jul 2021
Shares of Viatris Inc. gained 3.3% in premarket trading on Thursday, the day after the Food and Drug Administration approved the first biosimilar verson of insulin glargine from Viatris and Biocon Bio
Sanofi Q2 Performance Benefits From Dupixent, Vaccines; Raises 2021 Profit Forecast
07:19am, Thursday, 29'th Jul 2021
Sanofi SA (NASDAQ: SNY) has raised its 2021 profit forecast after its vaccines and blockbuster eczema treatment Dupixent helped boost second-quarter results. Q2 2021 sales grew 6.55 Y/Y to €8.7 bi
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients
07:06am, Thursday, 29'th Jul 2021
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe ch
